It's an adaptive study. There could be recommendations on the eligibility criteria. At the moment the criteria could be so broad that a number of patients (ie. unfortunately the worse of the worse) who due to complex organ failure and other similar issues that are beyond the scope of the drug to treat are significantly impacting the results (ie. either negatively or making it hard to determine the effect on virus recovery).

They could be recommending to get better results, be more selective. I suspect that may be part of their recommendations.